GCANRx Announces Relisting To OTCQB Market Tier

Rhea-AI Summary

Greater Cannabis Company (OTC: GCAN) announced that its common stock was approved for quotation on the OTCQB Venture Market effective December 3, 2025. To qualify, companies must meet higher financial and disclosure standards and follow best-practice corporate governance. The company says the move should provide enhanced investor benefits, including higher reporting standards, greater access to analyst coverage and news services, and more comprehensive compliance. The OTCQB is recognized by the SEC as an established public market for determining public market price for resale registrations.

U.S. investors can find current financial disclosure and Real-Time Level 2 quotes on otcmarkets.com. For investor inquiries visit gcanrx.com or contact info@gcanrx.com.

Positive

• Shares approved for quotation on OTCQB (December 3, 2025)
• Higher reporting standards and management certification
• Greater access to analyst coverage, news services and broker-dealer trading
• OTCQB recognized by the SEC as an established public market for resale pricing

Negative

• More comprehensive compliance requirements increase reporting obligations
• Requirement to meet high financial standards and governance may raise administrative burden

Baltimore, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Greater Cannabis Company, Inc. (OTC: GCAN) (“the Company”), a clinical stage biopharmaceutical company focused on the development of new and effective cannabinoid therapeutics, today announced that shares of its common stock were approved for quotation on the OTCQB^® Venture Market. To qualify for this market, companies must meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws and be current in their disclosure. The Company believes that the move to the OTCQB will provide enhanced investor benefits including higher reporting standards, greater access to analyst coverage and news services, and more comprehensive compliance requirements. The OTCQB is considered by the Securities and Exchange Commission (SEC) as an “established public market” for the purpose of determining the public market price when registering securities for resale with the SEC. The OTCQB dramatically increases transparency, reporting standards, management certification and compliance requirements. The majority of broker dealers trade stocks on the OTCQB. Historically this has resulted in greater liquidity and awareness for companies that reach the OTCQB tier.

To learn more, visit OTCQB. U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.

ENDS

For GCANRx Investor Relations inquiries visit www.gcanrx.com, or contact info@gcanrx.com. To receive the latest information about GCANRx sign up to the investor email at https://bit.ly/2ZNlBoj or follow @GCANRX on Twitter.

About Greater Cannabis Company: The Greater Cannabis Company (OTC: GCAN), (“GCANRx” or the “Company”) is a publicly traded clinical stage biopharmaceutical company focused on the development of new and effective cannabinoid therapeutics. The Company conducts medical research, and is pursuing clinical trials, to develop innovative cannabis-based treatments for various medical conditions and their symptoms with an initial focus on neuropsychiatric disorders. GCANRx’s mission is to bring its products to the global market for the benefit of patients seeking better solutions for their unmet medical needs.

Disclaimer: Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not strictly historical are “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve a high degree of risk and uncertainty, are predictions only and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include the uncertainty regarding viability and market acceptance of the Company’s products and services, the ability to complete development plans in a timely manner, changes in relationships with third parties, product mix sold by the Company and other factors described in the Company’s most recent periodic filings with the Securities and Exchange Commission, including its 2020 Annual Report on Form 10-K and quarterly reports on Form 10-Q.

Forward-Looking Statements: This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact: The Greater Cannabis Company, Inc.
443-738-4051
info@gcanrx.com
www.gcanrx.com

FAQ

What did Greater Cannabis Company (GCAN) announce on December 3, 2025?

The company announced its common stock was approved for quotation on the OTCQB Venture Market.

How does GCAN’s move to the OTCQB affect investor information and transparency?

The move brings higher reporting standards, management certification, and more comprehensive disclosure requirements.

Will GCAN shares be available for real-time quotes after the OTCQB relisting?

Yes; U.S. investors can find current financial disclosure and Real-Time Level 2 quotes on otcmarkets.com.

Does the OTCQB designation help when registering GCAN securities for resale with the SEC?

Yes; the OTCQB is considered an established public market by the SEC for determining public market price for resale registrations.

What investor benefits did GCAN cite for moving to OTCQB on December 3, 2025?

The company cited greater analyst coverage, improved news distribution, higher reporting standards, and broader broker-dealer trading.